Abstract
Interferon (IFN)-α is involved in the pathogenesis of systemic lupus erythematosus. Studies in murine lupus models have revealed that type I IFN exerts either a protective effect in MRL/lpr, or can detrimentally impact disease progression, as in NZB/W mice. To understand this paradox, we examined the kinetic global gene expression in pre-autoimmune NZB/W-, MRL/lpr- and normal BALB/c-derived splenic mononuclear cells following ex vivo IFN-α treatment. Analysis of IFN-α-induced gene expression patterns revealed genes associated with antiproliferative activity of IFN-α including CDKN1A, GADD45B, pituitary tumor-transforming 1, SCOTIN, ataxia telangiectasia-mutated homolog and calcyclin-binding protein were upregulated in MRL/lpr and/or BALB/c mice. Of IFN-α-induced genes differentially expressed in NZB/W vs BALB/c and MRL/lpr mice at 3 h time point, enhanced expression of CCND1, cyclin D2, matrix metalloproteinase 13 and a panel of cytokines and chemokines and impaired expression of negative inflammatory regulators CD69 and an Src family kinase hemopoietic cell kinase were notable. Interestingly, the splenic mononuclear cells from the NZB/W not MRL/lpr lupus-prone mice at the pre-autoimmune stage before ex vivo IFN-α treatment, have increased expression of many known IFN-regulated genes. These results provide a unique genomic view of ex vivo IFN-α response in two lupus-prone models, and help to have an insight into the role of IFN-α in lupus pathogenesis
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
Accessions
GenBank/EMBL/DDBJ
References
Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL . Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5–8.
Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610–2615.
Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711–723.
Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY . Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003; 4: 177–186.
Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK . Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491–1503.
Crow MK, Kirou KA, Wohlgemuth J . Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003; 36: 481–490.
Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777–788.
Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S . IFN-α induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J Immunol 2005; 174: 2499–2506.
Hron JD, Peng SL . Type I IFN protects against murine lupus. J Immunol 2004; 173: 2134–2142.
Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner W et al. Interferon-β: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J Am Soc Nephrol 2005; 16: 3264–3272.
Hadj-Slimane R, Chelbi-Alix MK, Tovey MG, Bobe P . An essential role for IFN-α in the overexpression of Fas ligand on MRL/lpr lymphocytes and on their spontaneous Fas-mediated cytotoxic potential. J Interferon Cytokine Res 2004; 24: 717–728.
Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S . Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314–317.
Ronnblom LE, Alm GV, Oberg K . Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 1991; 30: 537–540.
Niewold TB, Swedler WI . Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005; 24: 178–181.
Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992; 65: 70–74.
Hahn BH . Animal models of systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds). Dubois’ Lupus Erythematosus, 6th edn. Lippincott Williams and Wilkins: Philadelphia, 2002, pp 339–388.
Theofilopoulos AN . Murine models of lupus. In: Lahita RG (eds). Systemic Lupus Erythematosus. Churchill Livingston: New York, 1992, pp 121.
Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, Ivashkiv LB . IFN-α priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol 2004; 172: 6476–6481.
Dorner BG, Scheffold A, Rolph MS, Hüser MB, Kaufmann SHE, Radbruch A et al. MIP-1α, MIP-1β, RANTES, and ATAC/lymphotactin function together with IFN-γ as type 1 cytokines. Proc Natl Acad Sci USA 2002; 99: 6181–6186.
Dyson N . The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245–2262.
Hamid T, Kakar SS . PTTG/securing activates expression of p53 and modulates its function. Mol Cancer 2004; 3: 18.
Yu R, Heaney AP, Lu W, Chen J, Melmed S . Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem 2000; 275: 36502–36505.
Pusapati RV, Rounbehler RJ, Hong S, Powers JT, Yan M, Kiguchi K et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci USA 2006; 103: 1446–1451.
Fukushima T, Zapata JM, Singha NC, Thomas M, Kress CL, Krajewska M et al. Critical function for SIP, a ubiquitin E3 ligase component of the beta-catenin degradation pathway, for thymocyte development and G1 checkpoint. Immunity 2006; 24: 29–39.
el-Deiry WS, Harper JW, O’Connor PM, Velcul escu VE, Canman CE, Jackman J et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169–1174.
Matsuoka M, Tani K, Asano S . Interferon-alpha-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p19Ink4D and p21Cip1 in mouse macrophage. Oncogene 1998; 16: 2075–2086.
Zhan Q, Antinore MJ, Wang XW, Carrier F, Smith ML, Harris CC et al. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene 1999; 18: 2892–2900.
Santiago-Raber ML, Lawson BR, Dummer W, Barnhouseb M, Koundouris S, Wilson CB et al. Role of cyclin kinase inhibitor p21 in systemic autoimmunity. J Immunol 2001; 167: 4067–4074.
Goulvestre C, Chereau C, Nicco C, Mouthon L, Weill B, Batteux F . A mimic of p21WAF1/CIP1 ameliorates murine lupus. J Immunol 2005; 175: 6959–6967.
Liu L, Tran E, Zhao YN, Huang YC, Flavell R, Lu BF . Gadd45β and Gadd45γ are critical for regulating autoimmunity. J Exp Med 2005; 202: 1341–1347.
Waldmann TA . Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. Arthritis Res Ther 2004; 6: 174–177.
Moon JJ, Rubio ED, Martino A, Krumm A, Nelson BH . Permissive role for phosphatidylinositol 3-kinase in the Stat5-mediated expression of cyclin D2 by the interleukin-2 receptor. J Biol Chem 2004; 279: 5520–5527.
Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J et al. Analysis of 16 different matrix metalloproteinases (MMP-1–MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999; 58: 691–697.
Yahata T, de Caestecker MP, Lechleider RJ, Andriole S, Roberts AB, Isselbacher KJ et al. The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors. J Biol Chem 2000; 275: 8825–8834.
Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, d’Eckner A et al. Cooperation of Stat2 and p300/CBP in signaling induced by interferon-a. Nature 1996; 383: 344–347.
Sancho D, Gomez M, Viedma F, Esplugues E, Gordon-Alonso M, Garcia-Lopez MA et al. CD69 downregulates autoimmune reactivity through active transforming growth factor-β production in collagen-induced arthritis. J Clin Invest 2003; 112: 872–882.
Zhang H, Meng F, Chu CL, Takai T, Lowell CA . The Src family kinases Hck and Fgr negatively regulate neutrophil and dendritic cell chemokine signaling via PIR-B. Immunity 2005; 22: 235–246.
JØrgensen TN, Gubbels MR, Kotzin BL . Links between type I interferon and the genetic basis of disease in mouse lupus. Autoimmunity 2003; 36: 491–502.
Vyse TJ, Drake CG, Rozzo SJ, Roper E, Izui S, Kotzin BL . Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice. J Clin Invest 1996; 98: 1762–1772.
Morel L, Rudofsky UH, Longmate JA, Schiffenbauer J, Wakeland EK . Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994; 1: 219–229.
Mohan C, Alas E, Morel L, Yang P, Wakeland EK . Genetic dissection of SLE pathogenesis Sle 1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J Clin Invest 1998; 101: 1362–1372.
Kono DH, Burlingame RW, Owens DG, Kuramochi A, Balderas RS, Balomenos D et al. Lupus susceptibility loci in New Zealand mice. Proc Natl Acad Sci USA 1994; 91: 10168–10172.
Kawai T, Takeuchi O, Fujita T, Inoue JI, Mühlradt PF, Sato S et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 2001; 167: 5887–5894.
Toshchakov V, Jones BW, Perera PY, Thomas K, Cody MJ, Zhang S et al. TLR4, but not TLR2, mediates IFN-β-induced STAT1á/β-dependent gene expression in macrophages. Nat Immunol 2002; 3: 392–398.
Wu C, Ohmori Y, Bandyopadhyay S, Sen G, Hamilton T . Interferon-stimulated response element and NFB sites cooperate to regulate double-stranded RNA-induced transc. J Interferon Res 1994; 6: 357–363.
Nakaya T, Sato M, Hata N, Asagiri M, Suemori H, Noguchi S et al. Gene induction pathways mediated by distinct IRFs during viral infection. Biochem Biophys Res Commun 2001; 283: 1150–1156.
Gresser I, Vignaux F, Belardelli F, Tovey MG, Maunoury MT . Injection of mice with antibody to mouse interferon α/β decreases the level of 2′–5′ oligoadenylate synthetase in peritoneal macrophages. J Virol 1985; 53: 221–227.
Qian L, Liu Y, Sun HB, Yokota H . Systems analysis of matrix metalloproteinase mRNA expression in skeletal tissues. Front Biosci 2002; 7: a126–a134.
Li WQ, Dehnade F, Zafarullah M . Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 2001; 166: 3491–3498.
Sun HB, Zhu YX, Yin T, Sledge G, Yang YC . MRG1, the product of a melanocyte-specific gene related gene, is a cytokine-inducible transcription factor with transformation activity. Proc Natl Acad Sci USA 1998; 95: 13555–13560.
Leung MK, Jones T, Michels CL, Livingston DM, Bhattacharya S . Molecular cloning and chromosomal localization of the human CITED2 gene encoding p35srj/Mrg1. Genomics 1999; 61: 307–313.
Tien ES, Davis JW, Vanden Heuvel JP . Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor a coregulator. J Biol Chem 2004; 279: 24053–24063.
Delerive P, Fruchat JC, Staels B . Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169: 453–459.
Zhu M, John S, Berg M, Leonard WJ . Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. Cell 1999; 96: 121–130.
Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3: 2274–2284.
Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I et al. Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963–969.
Elbourne KB, Keisler D, McMurray RW . Differential effects of estrogen and prolactin on autoimmune disease in the NZB/W mouse model of SLE. Lupus 1998; 7: 420–427.
McMurray R, Keisler D, Kanuckel K, Izui S, Walker S . Prolactin influences autoimmune disease activity in the female NZB/W mouse. J Immunol 1991; 147: 3780–3787.
Horwitz GA, Miklovsky I, Heaney AP, Ren SG, Melmed S . Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression. Mol Endocrinol 2003; 17: 600–609.
Acknowledgements
We thank HF Wang for assistance in data analysis. The work was supported by grants from the Shanghai Commission of Science and Technology (06JC14050), Shanghai leading Academic Discipline project (T0203), Chinese Natural Science Foundation Grant (30471613), China Postdoctoral Science Foundation (20060390634) and Shanghai Postdoctoral Science Foundation (06R214144).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Genes and Immunity website (http://www.nature.com/gene)
Rights and permissions
About this article
Cite this article
Lu, Q., Shen, N., Li, X. et al. Genomic view of IFN-α response in pre-autoimmune NZB/W and MRL/lpr mice. Genes Immun 8, 590–603 (2007). https://doi.org/10.1038/sj.gene.6364421
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gene.6364421
Keywords
This article is cited by
-
Altered gene expression and PTSD symptom dimensions in World Trade Center responders
Molecular Psychiatry (2022)
-
NKG2D+CD4+ T Cells Kill Regulatory T Cells in a NKG2D-NKG2D Ligand- Dependent Manner in Systemic Lupus Erythematosus
Scientific Reports (2017)
-
MicroRNAs—novel regulators of systemic lupus erythematosus pathogenesis
Nature Reviews Rheumatology (2012)
-
Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance
Arthritis Research & Therapy (2010)
-
Interferon-α and -β in kidney inflammation
Kidney International (2010)